Background COPD frequently coexists with HF with which shares several risk factors. A greater collaboration is required between cardiologists and pulmonologists to better identify and manage concurrent HF and COPD. This observational, retrospective study provides new data regarding the management of these patients. Methods from the Health Search Database which collects information generated by the routine activity of general practitioners, we selected 803 patients suffering from COPD or HF alone or combined analyzing similarities and differences regarding risk factors, diagnostic workup and therapeutic approaches. Main results Statistical analyses have evidenced significant differences regarding exposure to cigarette smoke and the prevalence of diabetes and hypertension in the three groups of patients. As regard to the diagnostic workup, it has been found that the 63,9% of COPD patients and the 57,1% of COPD + HF patients performed a spirometry vs the 95,4% of HF patients and the 95,2% of COPD + HF patients that performed an ECG. Regarding the pharmacologic treatment, the 47% of COPD patients was treated with an ICS/LABA association and the 22% with ICS/LABA + LAMA. In the COPD + HF group, 47% of patients were treated with ICS/LABA association, while 32% of these patients were treated with ICS/LABA + LAMA. The pharmacologic treatment most prescribed in HF was β-blockers (68%), diuretics (92.8%), antiplatelet therapy (55.6%) and ACE inhibitors (38.1%). In the COPD + HF group, β-blockers (40.1%), diuretics (89.8%), antiplatelet therapy (57.1%) and ACE inhibitors (44.9%) were prescribed. Conclusion this study has evidenced a disparity in performing instrumental diagnosis between COPD and HF groups that persists when both conditions coexist. Moreover, the pharmacological treatment of the two conditions shows a consistent under treatment with bronchodilators in COPD patients and with β-blockers in HF patients.

Prevalence and management of COPD and heart failure comorbidity in the general practitioner setting / Pirina, Pietro; Spada, Claudia; Zinellu, Elisabetta; Fois, Alessandro Giuseppe; Martinetti, Marco; Pes, Rosanna; Chessa, Efisio; Miravitlles, Marc; Pais, A.; Cosseddu, S.; Dessì, M. A.; Accardo, G.; Frau, D.; Peruzzu, I.; Uda, F.; Idda, G.; Sini, C.; Piro, S.; Muscas, A.; Arno, P.; Manca, A.; Serra, F.; Deiana, G.; Pintori, G.; Canu, M. G.; Fanari, G.; Setzu, S.; Vaccargiu, A. M.; Vincis, B.; Schirru, M. T.; Maureddu, P. P.; Dall'Acqua, P.; Contini, R.; Meloni, M.; Martinetti, M.; Granara, A. R.; Massa, S.; Cadeddu, M. G.; Mariani, B.; Urru, C.; Ambu, R.; Meloni, M. C.; Puddu, S.; Spano, F.; Musa, S.; Corona, M.. - In: RESPIRATORY MEDICINE. - ISSN 0954-6111. - 131:(2017), pp. 1-5. [10.1016/j.rmed.2017.07.059]

Prevalence and management of COPD and heart failure comorbidity in the general practitioner setting

Pirina, Pietro;SPADA, Claudia;Zinellu, Elisabetta;Fois, Alessandro Giuseppe;Dessì, M. A.;FRAU, DENISE;UDA, Francesco;MUSCAS, Alessandra;CANU, Maria Grazia;Contini, R.;Martinetti, M.;MASSA, Savina Dolores;Ambu, Rossano;Meloni, M. C.;MUSA, Stefano;
2017

Abstract

Background COPD frequently coexists with HF with which shares several risk factors. A greater collaboration is required between cardiologists and pulmonologists to better identify and manage concurrent HF and COPD. This observational, retrospective study provides new data regarding the management of these patients. Methods from the Health Search Database which collects information generated by the routine activity of general practitioners, we selected 803 patients suffering from COPD or HF alone or combined analyzing similarities and differences regarding risk factors, diagnostic workup and therapeutic approaches. Main results Statistical analyses have evidenced significant differences regarding exposure to cigarette smoke and the prevalence of diabetes and hypertension in the three groups of patients. As regard to the diagnostic workup, it has been found that the 63,9% of COPD patients and the 57,1% of COPD + HF patients performed a spirometry vs the 95,4% of HF patients and the 95,2% of COPD + HF patients that performed an ECG. Regarding the pharmacologic treatment, the 47% of COPD patients was treated with an ICS/LABA association and the 22% with ICS/LABA + LAMA. In the COPD + HF group, 47% of patients were treated with ICS/LABA association, while 32% of these patients were treated with ICS/LABA + LAMA. The pharmacologic treatment most prescribed in HF was β-blockers (68%), diuretics (92.8%), antiplatelet therapy (55.6%) and ACE inhibitors (38.1%). In the COPD + HF group, β-blockers (40.1%), diuretics (89.8%), antiplatelet therapy (57.1%) and ACE inhibitors (44.9%) were prescribed. Conclusion this study has evidenced a disparity in performing instrumental diagnosis between COPD and HF groups that persists when both conditions coexist. Moreover, the pharmacological treatment of the two conditions shows a consistent under treatment with bronchodilators in COPD patients and with β-blockers in HF patients.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11388/203437
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 19
  • ???jsp.display-item.citation.isi??? 17
social impact